DUXAP8 and hepatocellular carcinoma: As shown in Figure 5I, the knockdown of DUXAP8 enhanced the chemosensitivity of HCC cells to sorafenib, while DUXAP8 overexpression decreased the chemosensitivity of HCC cells to sorafenib, both results could be reversed by the knockdown and overexpression of miR-584-5p, respectively.